CLL Coverage from Every Angle
Advertisement
Advertisement

Recent News

SOHO 2021: Early-Phase Results With Novel BTK Inhibitor in CLL
SOHO 2021: Understanding Clinical Outcomes in Patients With CLL Older Than 80
SOHO 2021: Case-Based Look at First-Line Therapy for Younger Patients With CLL
SOHO 2021: Can the Natural History of Immune Dysfunction and Infections in CLL Be Altered?
COVID-19 in Patients With CLL: Is Neutropenia a Risk Factor?
Predicting Survival in Patients With CLL: Focus on TP53 Mutations
Statin Use in Patients With CLL: Impact on Survival Outcomes
Can the NOTCH Network Be Used to Refine Risk Stratification in CLL?
Karyotypic Complexity and Evolution May Impact Survival of Ibrutinib-Treated Patients With CLL
Managing CLL During the COVID-19 Pandemic: An Italian Report
Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL
How Does Acalabrutinib Measure Up Against Ibrutinib in CLL in Phase III Trial?
Case Study: Autoimmune Hemolytic Anemia in Male Patient With CLL
Ibrutinib Plus Venetoclax in CLL: Oral Nonchemotherapy Regimen Under Study
Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization
Retrospective Look at Therapeutic Considerations for Adolescent and Young Adults With CLL
Multi-hit TP53-Aberrant CLL: Focus on Prognostication and Management
Can Baseline Geriatric Domains Help to Identify High-Risk Patients With CLL?
Novel BCL2 Inhibitor Under Study in Resistant CLL and Other Blood Cancers
Antibody Response to COVID-19 Vaccine in Patients With CLL
EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab
ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL
What Next? Update on Management of Resistant CLL After First-Line Therapy
EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab
ASCO 2021: 4-Year Update of ELEVATE-TN Trial of Acalabrutinib Regimens in CLL
EHA2021: ALPINE Trial of Zanubrutinib Versus Ibrutinib in Resistant CLL
EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy
ASCO 2021: Fixed-Duration Treatment With Ibrutinib Plus Venetoclax in CLL
ASCO 2021: Phase III Noninferiority Trial of Acalabrutinib Versus Ibrutinib in CLL
Richter’s Transformation in CLL: B-Cell Receptor Signals and Genetic Lesions
Impact of Ibrutinib on T-Cell Responses in CLL
Rare Case of Metastatic CLL Presenting as Focal Mass in the Gallbladder
Deletion 17p Subclones and Outcomes in Patients With CLL
FDA Brief: New Drug Application Accepted for CD20-Targeted CAR T-Cell Therapy for CLL
Genetic Relationship Between CLL and Non-Melanoma Skin Cancer?
Does Ibrutinib Therapy Induce Host Antitumor Immune Activation in CLL?
Potential Biomarkers in CLL Harboring Trisomy 12 Under Study
Case Study: Rare Richter Transformation of CLL Involving the Ear
Untangling Neutrophil Clues to Increased Bacterial Infections in CLL
Serum APRIL Levels: Novel Prognostic Marker Under Study in CLL
Rare Case of Acute Macular Neuroretinopathy in a Woman With CLL
AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL
Concurrent Adenoid Cystic Carcinoma and CLL: Case Report
Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL
Identifying Prognostic Markers for Early-Stage CLL
Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported
High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.